The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial
JMIR Research Protocols · 23.07.2026 · 15 · e98352-e98352
DOI: 10.2196/98352 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 23.07.2026. Verfasst von Elizabeth N Madva und 16 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Mass General Brigham, 55 Fruit Street, Boston, MA, 02114, United States, 1-617-726-2000. Hauptthemen laut MEDLINE: Behavior Therapy, Irritable Bowel Syndrome, Psychology, Positive. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of positive psychological well-being, have been linked to improved health outcomes across diverse medical populations, they have not yet been investigated in IBS. To address this gap, we developed WISH (Well-Being in IBS: Strengths and Happiness), a novel, 9-week, phone-delivered PP-based BGBT for individuals with IBS.
Objective
This randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of a 9-week phone-delivered PP intervention for IBS compared with a time- and attention-matched educational control.
Methods
The WISH 2.0 trial is a parallel-group, 9-week pilot RCT that aims to enroll 50 adults meeting Rome IV criteria for IBS. Participants are randomized (1:1), stratified by IBS subtype and gender, to either the WISH 2.0 intervention or an educational control condition. Both conditions consist of 9 weekly 30-minute phone sessions accompanied by weekly manualized exercises. Primary outcomes are feasibility (proportion completing ≥6 of 9 sessions) and acceptability (weekly ease and utility ratings). Secondary outcomes include WISH 2.0’s preliminary effects on health-related, health behavior, and psychological outcomes, assessed at 4 time points: baseline, intervention midpoint, the postintervention assessment, and the 3-month postintervention assessment. Candidate gut-brain mechanisms that might underlie WISH 2.0’s effects, including changes in autonomic function (heart rate variability), interoception (self-report measure), gene expression (whole transcriptome RNA sequencing), and immune system activity (serum inflammatory biomarkers), will be explored before and after the intervention.
Results
The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered at ClinicalTrials.gov in March 2025. Funding was awarded in June 2025. Following a study start-up period, recruitment commenced in October 2025 and is ongoing. As of July 2026, 20 participants have been enrolled. Study completion is anticipated in August 2028.
Conclusions
This trial will determine the feasibility and acceptability of WISH 2.0, a novel PP intervention for IBS. Comparative results between WISH 2.0 and an educational control, including the possibility of equivalent outcomes, will provide important mechanistic insights and facilitate further optimization of BGBTs for IBS, informing a future fully powered efficacy trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Harvard Medical School, Mass General Brigham, 55 Fruit Street, Boston, MA, 02114, United States, 1-617-726-2000.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
- Division of Behavioral & Mental Health, Emory + Children's Pediatric Institute, Atlanta, GA, United States.
- Department of Physical Medicine & Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, Boston, MA, United States.
- Department of Pathology, Harvard Medical School, Mass General Brigham, Boston, MA, United States.
- Division of Digestive and Liver Diseases, Columbia University, NewYork-Presbyterian Hospital, New York, NY, United States.
ORCID-Profile: Elizabeth N Madva, Jeff C Huffman, Helen Burton-Murray, Emmett McGranaghan, Megan Bidgood, Jenny Y Gan, Benjamin Wasserman, Emily H Feig, Brian Healy, Kyle Staller, Bonney Reed, Roberta Sclocco, Sami S Amr, Stephen Bartels, Braden Kuo, Laurie Keefer, Christopher M Celano
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
Zitieren
APA
Madva, E. N., Huffman, J. C., Burton-Murray, H., McGranaghan, E., Bidgood, M., Gan, J. Y., Wasserman, B., Feig, E. H., Healy, B., Staller, K., Reed, B., Sclocco, R., Amr, S. S., Bartels, S., Kuo, B., Keefer, L., & Celano, C. M. (2026). The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 15, e98352-e98352. https://doi.org/10.2196/98352
Vancouver
Madva EN, Huffman JC, Burton-Murray H, McGranaghan E, Bidgood M, Gan JY, et al. The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols. 2026;15:e98352-e98352. doi:10.2196/98352
BibTeX
@article{Madva2026,
author = {Madva, Elizabeth N and Huffman, Jeff C and Burton-Murray, Helen and McGranaghan, Emmett and Bidgood, Megan and Gan, Jenny Y and Wasserman, Benjamin and Feig, Emily H and Healy, Brian and Staller, Kyle and Reed, Bonney and Sclocco, Roberta and Amr, Sami S and Bartels, Stephen and Kuo, Braden and Keefer, Laurie and Celano, Christopher M},
title = {The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e98352--e98352},
doi = {10.2196/98352}
}
EUVIMED